POTENTIAL APPLICATION OF DENDRIMERS IN DRUG DELIVERY: A CONCISE REVIEW AND UPDATE

  • Sunil Kumar Parajapati Dept. of Pharmacy, Bundelkhand University, Jhansi, India
  • Sheo Datta Maurya Dept. of Pharmacy, IEC Group of Institution, Greater Noida, India
  • Manas K Das Dept. of Pharmacy, IEC Group of Institution, Greater Noida, India
  • Vijay Kumar Tilak Dept. of Pharmacy, IEC Group of Institution, Greater Noida, India
  • Krishna Kr Verma Ram-Eish Institute of Pharmacy, Greater noida, India
  • Ram C Dhakar Jhalawar Medical College & Hospital, Jhalawar, India

Abstract

This review gives concise information about the application of dendrimers in the field of drug delivery. Due to their unique architecture these have improved physical and chemical properties. Due to their terminal groups these show high solubility, miscibility and reactivity. Dendrimers have well defined size, shape, molecular weight and monodispersity. These properties make the dendrimers a suitable carrier in drug delivery application. Dendrimers are unimolecular miceller in nature and due to this enhances the solubility of poorly soluble drugs. Their compatibility with DNA, heparin and polyanions make them more versatile. Dendrimers, also referred as modern day polymers, they offer much more good properties than the conventional polymers. Due to their multivalent and mono disperse character dendrimers have stimulated wide interest in the field of chemistry biology, especially in applications like drug delivery, gene therapy and chemotherapy. Self assembly produces a faster means of generating nanoscopic functional and structural systems. But their actual utility in drug delivery can be assessed only after deep understanding of factors affecting their properties and their behavior in vivo.

Key words: Dendrimers, Drug targeting, nanoscale carriers.

Downloads

Download data is not yet available.

Author Biographies

Sunil Kumar Parajapati, Dept. of Pharmacy, Bundelkhand University, Jhansi, India
Professor, Dept. of Pharmacy, Bundelkhand University, Jhansi, India
Sheo Datta Maurya, Dept. of Pharmacy, IEC Group of Institution, Greater Noida, India

Dept. of Pharmacy, IEC Group of Institution, Greater Noida, India

Manas K Das, Dept. of Pharmacy, IEC Group of Institution, Greater Noida, India

Dept. of Pharmacy, IEC Group of Institution, Greater Noida, India

Vijay Kumar Tilak, Dept. of Pharmacy, IEC Group of Institution, Greater Noida, India

Dept. of Pharmacy, IEC Group of Institution, Greater Noida, India

Krishna Kr Verma, Ram-Eish Institute of Pharmacy, Greater noida, India

Ram-Eish Institute of Pharmacy, Greater noida, India

Ram C Dhakar, Jhalawar Medical College & Hospital, Jhalawar, India

Jhalawar Medical College & Hospital, Jhalawar, India

References

1. Dwivedi Devendra Kumar, Singh Arun Kumar, Dendrimers: a novel carrier system for drug delivery, 2014; 4(5):1-6
2. D’Emanuele A, Jevprasesphant R, Penny J, Attwood D. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release 2004;95:5447–53.
3. Tomalia DA, Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog Polym Sci 2005;30:294–324.
4. Boas U, Jørn Bolstad Christensen, Heegaard PMH, “Dendrimers in medicine and biotechnology: new molecular tools”, 2006, 62-70
5. Mishra Ina, Dendrimer: a novel drug delivery system, Journal of Drug Delivery & Therapeutics; 2011; 1(2):70-74
6. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science 2004;303:1818‑22.
7. Soto‑Castro D, Cruz‑Morales JA, Ramírez Apan MT, Guadarrama P. Solubilization and anticancer‑activity enhancement of Methotrexate by novel dendrimeric nanodevices synthesized in one‑step reaction. Bioorg Chem 2012;41‑2:13‑21.
8. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 2005;57:2215‑2237.
9. Patton DL, Cosgrove Sweeney YT, McCarthy TD, Hillier SL. Preclinical safety and efficacy assessments of dendrimer‑based (SPL7013) microbicide gel formulations in a nonhuman primate model. Antimicrob Agents Chemother 2006;50:1696‑700.
10. Prajapati S., Maurya S., Das M., Tilak V., Verma K.K., Dhakar R.C., Dendrimers in drug delivery, diagnosis and therapy: basics and potential applications. Journal of Drug Delivery and Therapeutics, 2016; 6(1):67-92. Available at: . Date accessed: 25 Feb. 2016.
11. Hawker CJ and J.M. J. Fr´echet, “Preparation of polymers with controlled molecular architecture. A new convergent approach to dendriticmacromolecules,” Journal of the American Chemical Society, 1990; vol. 112, no. 21, pp. 7638–7647.
12. Esfand R and Tomalia DA, “Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications,” Drug Discovery Today, 2001; vol. 6, no. 8, pp. 427–436.
13. Kolhe P, Khandare J, Pillai O, Kannan S, Lieh-Lai M, and Kannan RM, “Preparation, cellular transport, and activity of polyamidoamine-based dendritic nanodevices with a high drug payload,” Biomaterials, 2006; vol. 27, no. 4, pp. 660–669.
14. Khandare JJ, Jayant S, Singhet A al., “Dendrimer versus linear conjugate: influence of polymeric architecture on the delivery and anticancer effect of paclitaxel,” Bioconjugate Chemistry, 2006; vol. 17, no. 6, pp. 1464–1472.
15. D’Emanuele A and Attwood D, “Dendrimer-drug interactions,” Advanced Drug Delivery Reviews, 2005, vol. 57, no. 15, pp. 2147– 2162.
16. Gupta U, Agashe HB, Asthana A, and Jain NK, “Dendrimers: novel polymeric nanoarchitectures for solubility enhancement,” Biomacromolecules, 2006; vol. 7, no. 3, pp. 649–658.
17. Aulenta F, Hayes W, and Rannard S, “Dendrimers: a new class of nanoscopic containers and delivery devices,” European Polymer Journal, 2003; vol. 39, no. 9, pp. 1741–1771.
18. Gillies ER and Fr´echet JMJ, “Dendrimers and dendritic polymers in drug delivery,” Drug Discovery Today, 2005; vol. 10, no. 1, pp. 35–43.
19. Menjoge AR, Kannan RM and Tomalia DA, Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications, Drug Discovery Today. 2010; 15(5/6):171-185.
20. Yang, H. and Lopina, S.T. Stealth dendrimers for antiarrhythmic quinidine delivery. J. Mater. Sci. Mater. Med. 2007, 18, 2061–2065.
21. Morgenroth F, Reuther E, Mullen K, Polyphenylene Dendrimers: From Three-Dimensional to Two-Dimensional Structures Angewandte Chemie, International Edition in English, 1997; 36 (6):631-634.
22. Nanjwade BK, Hiren M, Dendrimers: Emerging polymers for drug-delivery systems, Eur J Pharm Sci., 38 (3),2009, 185-196.
23. Sakthivel T, Florence AT. Dendrimers and dendrons: facets of pharmaceutical nanotechnology, Drug delivery technology, 2003; 73-78.
24. D’ Emanuele A, R. Jevprasephant. The use of a dendrimer – propranolol prodrug to bypass efflux transporters and enhance oral bioavailability, Journal of controlled release, 2004; 95: 447-453.
25. Cloninger MJ . Biological applications of dendrimers. Curr Opin Chem Biol 2002; 6:742‑8.
26. Jang WD, Kamruzzaman Selim KM, Lee CH, Kang IK. Bioinspired application of dendrimers: From bio‑mimicry to biomedical applications. Prog Polym Sci 2009; 34:1‑23.
27. Cheng Y, Wu Q, Li Y, Hu J, Xu T. New insights into the interactions between dendrimers and surfactants: 2. Design of new drug formulations based on dendrimer‑surfactant aggregates. J Phys Chem B 2009;113:8339‑46.
28. Jansen JF, de Brabander‑van den Berg EM, Meijer EW. Encapsulation of guest molecules into a dendritic box. Science 1994;266:1226 9.
29. D’Emanuele A, Attwood D. Dendrimer‑drug interactions. Adv Drug Deliv Rev 2005;57:2147‑62.
30. Parekh Hejal B, Jivani Rishad, Jivani NP, Patel LD, Makwana Ami, Sameja Krunal, Novel insitu polymeric drug delivery system: a review, Journal of Drug Delivery and Therapeutics, 2012; 2(5):136-145
31. Panda Priyabrata, Mishra Sangeet Sarita, Pati Kanhu Charan, Nano-medicine: an emerging trend in molecular delivery, Journal of Drug Delivery and Therapeutics, 2014: Special Issue1: "Drug Delivery using Nanomedicine & Nanotechnology", 98-106.
32. Kaur Harpreet, Singh Gurpreet, In-vivo methods to study uptake of nanoparticles into the brain, Journal of Drug Delivery and Therapeutics; 2013, 3(4):173-177
33. Yang H, “Nanoparticle-Mediated Brain-Specific Drug Delivery, Imaging and Diagnosis,” Pharmaceutical Re-search, Vol. 27, No. 9, 2010, pp. 1759-1771. doi:10.1007/s11095-010-0141-7
34. Leyuan Xu, Hao Zhang, Yue Wu, Dendrimer Advances for the Central Nervous System Delivery of Therapeutics, ACS Chem. Neurosci. 2014; 5:2−13
35. Nowacek, A., and Gendelman, H. E. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine. 2009; 4:557−574.
36. Wong, H. L., Wu, X. Y., and Bendayan, R. Nanotechnological advances for the delivery of CNS therapeutics. Adv. Drug Delivery Rev. 2012; 64, 686−700.
37. Kitchens KM, El-Sayed ME, Ghandehari H, “Transepithelial and Endothelial Transport of Poly(ami-doamine) Dendrimers,” Advanced Drug Delivery Reviews, Vol. 57, No. 2005, pp. 2163-2176.
38. Heather A. Bullen, Ruth Hemmer, Anthony Haskamp, Chevelle Cason, Stephen Wall et al, Evaluation of Biotinylated PAMAM Dendrimer Toxicity in Models of the Blood Brain Barrier: A Biophysical and Cellular Approach, Journal of Biomaterials and Nanobiotechnology, 2011, 2, 485-493
39. Katare YK, Daya Ritesh P., Gray CS, Luckham Roger E, Bhandari J, Chauhan Abhay S, Mishra Ram K, Brain Targeting of a Water Insoluble Antipsychotic Drug Haloperidol via the Intranasal Route Using PAMAM Dendrimer, Mol. Pharmaceutics 2015, 12, 3380−3388
40. Dhanikula RS, Hildgen P. Influence of molecular architecture of polyether-co-polyester dendrimers on the encapsulation and release of methotrexate. Biomaterials 2007;28:3140–52.
41. Dhanikula RS, Argaw A, Bouchard JF, Hildgen P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol Pharm 2008;5:105–16.
42. Prieto MJ, Schilrreff P, Tesoriero MVD, Morilla MJ, Romero EL. Brain and muscle of Wistar rats are the main targets of intravenous dendrimeric sulfadiazine. Int J Pharm 2008;360:204–12.
43. Singh S, Koland M, Formulation and evaluation of pulsatile drug delivery systems of glipizide for the management of type-II diabetes mellitus, Journal of Drug Delivery & Therapeutics. 2016; 6(1):11-18
44. Nyol S, Gupta MM, Immediate Drug Release Dosage Form: A Review, Journal of Drug Delivery & Therapeutics; 2013, 3(2), 155-161
45. Garg Ashish, Gupta M.M., Mouth Dissolving Tablets: A Review, Journal of Drug Delivery & Therapeutics; 2013; 3(2):207-214
46. Lin Y, Fujimori T, Kawaguchi N, et al. Polyamidoamine dendrimers as novel potential absorption enhancers for improving the small intestinal absorption of poorly absorbable drugs in rats. J Control Release 2011;149:21–8.
47. Sadekar S, Ghandehari H. Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery. Adv Drug Deliv Rev 2012;64:571–88.
48. Kolhe P, Misra E, Kannan RM, Kannan S, Lieh-Lai M. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm 2003;259:143–60.
49. Thaxton CS, Georganopoulou DG, Mirkin CA. Gold nanoparticle probes for the detection of nucleic acid targets. Clin Chim Acta 2006;363:120–6.
50. Dhakar Ram Chand, Maurya Sheo Datta, Tilak Vijay K, Gupta Anish K, A review on factors affecting the design of nasal drug delivery system, International Journal of Drug Delivery, 2011; 3 194-208
51. Dhakar RC, Nasal drug delivery: success through integrated device development, Journal of Drug Delivery & Therapeutics; 2011; 1(1):2-7.
52. Kapoor D, Vyas RB, Lad C, Patel M, Lal B, Site specific drug delivery through nasal route using bioadhesive polymers, Journal of Drug Delivery & Therapeutics. 2015; 5(1):1-9.
53. Dhuria SV, Hanson L R, Frey WH, II Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 2010, 99:1654−1673.
54. Thorne RG, Frey WH, Delivery of neurotrophic factors to the central nervous system - Pharmacokinetic considerations. Clin. Pharmacokinet. 2001, 40, 907−946.
55. Capsoni S, Marinelli S, Ceci M, Vignone D, Amato G et al. Intranasal ″painless″ Human Nerve Growth Factors Slows Amyloid Neurodegeneration and Prevents Memory Deficits in App X PS1Mice. PLoS One 2012, 7, e37555.
56. Bahadur S, Pathak K. Physicochemical and physiological considerations for efficient nose-to-brain targeting. Expert Opin. Drug Delivery 2012, 9, 19−31.
57. Zhang QZ, Zha LS, Zhang Y. Jiang WM, Lu W, Shi ZQ, Jiang XG, Fu SK. The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats. J. Drug Targeting 2006, 14, 281−290.
58. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-tobrain delivery of drugs. Int. J. Pharm. 2009, 379, 146−157.
59. Fazil M, Md S, Haque S, Kumar M, Baboota S, Sahni JK, Ali J. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur. J. Pharm. Sci. 2012, 47, 6−15.
60. Piazza J, Hoare T, Molinaro L, Terpstra K, Bhandari J, Selvaganapathy PR, Gupta B, Mishra RK. Haloperidol-loaded intranasally administered lectin functionalized poly(ethylene glycol)- block-poly(D,L)-lactic-co-glycolic acid (PEG- PLGA) nanoparticles for the treatment of schizophrenia. Eur. J. Pharm. Biopharm. 2014, 87, 30−39.
61. Kulhari H, Pooja D, Prajapati SK, Chauhan AS, Performance evaluation of PAMAM dendrimer based simvastatin formulations. Int. J. Pharm. 2011, 405, 203−209.
62. Perez AP, Mundina-Weilenmann C, Romero EL, Morilla MJ. Increased brain radioactivity by intranasal P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels. Int. J. Nanomed. 2012, 7, 1373−1385.
63. Kim, I.D.; Shin, J.H.; Kim, S.W.; Choi, S.; Ahn, J.; Han, P.L.; Park, J.S.; Lee, J.K. Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol. Ther. 2012, 20, 829–839.
64. Perez, A.P.; Mundina-Weilenmann, C.; Romero, E.L.; Morilla, M.J. Increased brain radioactivity by intranasal P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels. Int. J. Nanomedicine 2012, 7, 1373–1385.
65. Toub N, Malvy C, Fattal E, Couvreur P. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed Pharmacother 2006;60:607–20.
66. de Martimprey H, Vauthier C, Malvy C, Couvreur P. Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA. Eur J Pharm Biopharm 2009;71:490–504.
67. Dufès C, Uchegbu IF, Schätzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev 2005;57:2177–202.
68. Galletti R, Masciarelli S, Conti C, Matusali G, Di Renzo L, Meschini S, et al. Inhibition of Epstein Barr Virus LMP1 gene expression in B lymphocytes by antisense oligonucleotides: uptake and efficacy of lipid-based and receptor-mediated delivery systems. Antiviral Res 2007;74:102–10.
69. Tack F, Bakker A, Maes S, Dekeyser N, Bruining M, Elissen‑Roman C, et al. Modified poly (propylene imine) dendrimers as effective transfection agents for catalytic DNA enzymes (DNAzymes). J Drug Target 2006;14:69‑86.
70. Pandita D, Santos JL, Rodrigues J, Pêgo AP, Granja PL, Tomás H. Gene delivery into mesenchymal stem cells: A biomimetic approach using RGD nanoclusters based on poly (amidoamine) dendrimers. Biomacromolecules 2011;12:472‑81.
71. Santos JL, Oliveira H, Pandita D, Rodrigues J, Pêgo AP, Granja PL, et al. Functionalization of poly (amidoamine) dendrimers with hydrophobic chains for improved gene delivery in mesenchymal stem cells. J Control Release 2010;144:55‑64.
72. Santos JL, Pandita D, Rodrigues J, Pêgo AP, Granja PL, Balian G, et al. Receptor‑mediated gene delivery using PAMAM dendrimers conjugated with peptides recognized by mesenchymal stem cells. Mol Pharm 2010;7:763‑74.
73. Diaz-Mochon JJ, Fara MA, Sanchez-Martin RM, Bradley M. Peptoid dendrimers-microwave-assisted solid-phase synthesis and transfection agent evaluation. Tetrahedron Lett 2008;49:923–6.
74. Hussain M, Shchepinov MS, Sohail M, Benter IF, Hollins AJ, Southern EM, et al. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides. J Control Release 2004;99:139– 55.
75. Vincent L, Varet J, Pille J-Y, Bompais H, Opolon P, Maksimenko A, et al. Efficacy of dendrimer-mediated angiostatin and TIMP-2 gene delivery on inhibition of tumor growth and angiogenesis: in vitro and in vivo studies. Int J Cancer 2003;105:419–29.
76. Luo D, Haverstick K, Belcheva N, Han E, Saltzman WM. Poly(ethylene glycol)-Conjugated PAMAM dendrimer for biocompatible, high-efficiency DNA delivery. Macromolecules 2002;35:3456–62.
77. Lee SC, Parthasarathy R, Botwin K, Kunneman D, Rowold E, Lange G, Klover J et al, Biochemical and immunological properties of cytokines conjugated to dendritic polymers. Biomed. Microdevices 2004. 6, 191–202.
78. Chaves F, Calvo JC, Carvajal C, Rivera Z, Ramirez Let al, Synthesis, isolation and characterization of Plasmodium falciparum antigenic tetrabranched peptide dendrimers obtained by thiazolidine linkages. J. Pept. Res. 2001. 58, 307–316.
79. Heegaard PMH, Boas U, an Sorensen NS, “Dendrimers for vaccine and immunostimulatory uses. A review,” Bioconjugate Chemistry, 2010; vol. 21, no. 3, pp. 405–418.
80. Crespo L, Sanclimens G, Pons M, Giralt E, Royo M, and Albericio F, “Peptide and amide bond-containing dendrimers,” Chemical Reviews, 2005; vol. 105, no. 5, pp. 1663–1681.
81. Tam JP, “Multiple antigen peptide system,” US5229490A, 1993.
82. Chaum E et al. Polyplex-mediated gene transfer into human retinal pigment epithelial cells in vitro. J Cell Biochem 1999; 76: 153–160.
83. Vandamme TF and Brobeck L, "Poly(amidoamine) Dendrimers as Ophthalmic Vehicles for Ocular Delivery of Pilocarpine Nitrate and Tropicamide," J. Control. Rel. 2005; 102 (1), 23–38.
84. Boas U, Heegaard PM, Dendrimers in drug research, Chemical Society Reviews, 2004; 33(1):43-63.
85. Shaunak S et. al., "Polyvalent Dendrimer Glucosamine Conjugates Prevent Scar Tissue Formation," Nature Biotechnol. 2004; 22 (8), 977–984.
86. Marano RJ et al., "Dendrimer Delivery of an Anti-VEGF Oligonucleotide into the Eye: A Long-Term Study into Inhibition of Laser-Induced CNV, Distribution, Uptake, and Toxicity,"Gene Ther. 2005; 12 (1), 1544–1550.
87. Yao WJ, Sun KX, Mu HJ et al., “Preparation and characterization of puerarindendrimer complexes as an ocular drug delivery system,” Drug Development and Industrial Pharmacy, vol. 36, no. 9, pp. 1027–1035, 2010.
88. Holden CA, Tyagi P, Thakur A et al., “Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs,” Nanomedicine, vol. 8, no. 5, pp. 776–783, 2012.
89. Thomas BJ, Finnin BC. 2004. The transdermal revolution. Drug Discov Today 9:697–703.
90. Wang ZX, Itoh Y, Hosaka Y, Kobayashi I, Nakano Y, Maeda I, Umeda F, Yamakawa J, Kawase M, Yag K. 2003. Novel transdermal drug delivery system with polyhydroxyalkanoate and starburst polyamidoamine dendrimer. J Biosci Bioeng 95: 541–543.
91. Cheng Y et al., "Transdermal Delivery of Nonsteroidal Anti-Inflammatory Drugs Mediated by Polyamidoamine (PAMAM) Dendrimers," J. Pharm. Sci. 2007; 96 (3), 595–602.
92. Chauhan AS et al., "Dendrimer-Mediated Transdermal Delivery: Enhanced Bioavailability of Indomethacin," J. Control. Rel. 2003, 90 (3), 335–343.
93. Kukowska-Latallo JF, Raczka E, Quintana A, Chen C, Rymaszewski M, Baker JR Jr. Intravascular and endobronchial DNA delivery to murine lung tissue using a novel, nonviral vector. Hum Gene Ther. 2000;11:1385–1395.
94. Rudolph C, Lausier J, Naundorf S, Muller RH, Rosenecker J. In vivo gene delivery to the lung using polyethylenimine and fractured polyamidoamine dendrimers. J Gene Med. 2000;2:269–278.
95. Bai S, Thomas C, Ahsan F. Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin. J Pharm Sci 2007; 96:2090–106.
96. Bai S, Ahsan F. Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. Pharm Res 2009;26:539-48.
97. Shuhua B and Fakhrul A. Synthesis and Evaluation of Pegylated Dendrimeric Nanocarrier for Pulmonary Delivery of Low Molecular Weight Heparin. Pharmaceutical Research 2004; 26(3): 539-548.
98. Bai S, Gupta V, Ahsan F. Cationic liposomes as carriers for aerosolized formulations of an anionic drug: safety and efficacy study. Eur J Pharm Sci 2009;38:165–71.
99. Chandel Priya, Raj Kumari, Kapoor Ankita, Liquisolid technique: an approach for enhancement of solubility Journal of Drug Delivery & Therapeutics; 2013; 3(4):131-137
100. Jain NK, Gupta U, Application of dendrimer-drug complexation in the enhancement of drug solubility and bioavailability, Expert Opin Drug Metab Toxicol, 2008; 2003:1035-1045.
101. Mohammad N, Antony D, Crossing cellular barriers using dendrimer nanotechnologies, Current Opinion in Pharmacology, 2006; 6:522–527.
102. Hecht S, Fre´chet JMJ, Dendritic encapsulation of function: applying nature’s site isolation principle from biomimetics to materials science, Angew. Chem., Int. Ed. Engl., 2001, 40:74–91.
103. Jiang DL, Aida T, A dendritic iron porphyrin as a novel haemoproteinmimic: effects of the dendrimer cage on dioxygenbinding activity, Chem. Commun, 1996, 1523–1524.
104. Sharma Deepak, Kumar Dinesh, Singh Gurmeet, Singh Mankaran, Rathore Mahendra Singh, A review on current advances in nanotechnology approaches for the effective delivery of anti-cancer drugs, Journal of Drug Delivery and Therapeutics, 2014; Special Issue1: "Drug Delivery using Nanomedicine & Nanotechnology" 67-71
105. Kapil Aruna, Aggarwal Geeta, Harikumar SL, Nanotechnology in novel drug delivery system, Journal of Drug Delivery & Therapeutics; 2014, 4(5), 21-28
106. Asadujjaman Md., Mishuk Ahmed Ullah, Novel approaches in lipid based drug delivery systems, Journal of Drug Delivery & Therapeutics; 2013; 3(4):124-130
107. Yadav Geeta, Panchory Hiten, Nanosponges: a boon to the targeted drug delivery system, Journal of Drug Delivery & Therapeutics. 2013; 3(4):151-155.
108. Lohumi Ashutosh, Rawat Suman, Sarkar Sidhyartha, Sipai Altaf bhai., Yadav M. Vandana, A novel drug delivery system: niosomes review, Journal of Drug Delivery & Therapeutics. 2012; 2(5):129-135
109. Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Progress in Polymer Science, 2014; 39(2):268-307.
110. Iyer AK, Khaled G, Fang J, Maeda H, Exploiting the enhanced permeability and retention effect for tumor targeting, Drug Discov. Today, 11 (2006) 812–818.
111. Myc A, Majoros IJ, Thomas TP, Baker JR Jr. Dendrimer‑based targeted delivery of an apoptotic sensor in cancer cells. Biomacromolecules 2007;8:13-18.
112. Lai P-S, Lou P-J, Peng C-L, Pai C-L, Yen W-N, Huang M-Y, et al. Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy. J Control Release 2007;122:39–46.
113. Wiwattanapatapee R, Lomlim L, Saramunee K. Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid. J Control Release 2003;88:1-9.
114. Dodziuk H, Demchuk OM, Schilf W, Dolgonos G, Synthesis. NMR study of a first generation dendrimer having four branches involving four glycine and one carbomoyl-(3,7-dimethoxy-2- naphthalene) groups and attempts to complex it with α-, β- or γ-cyclodextrins. J Mol Struct 2004;693:145–51.
115. Muhanna AMA, Ortiz-Salmerón E, GarcIa-Fuentes L, Giménez- MartInez JJ, Vargas-Berenguel A. Synthesis of peptide dendrimers based on a β-cyclodextrin core with guest binding ability. Tetrahedron Lett 2003;44:6125–8.
116. Moghimi SM, Bonnemain B. 1999. Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: Applications in lymphoscintigraphy and indirect lymphography. Adv Drug Deliv Rev, 37:295–312.
117. Gebbia V, Puozzo C. 2005. Oral versus intravenous vinorelbine: Clinical safety profile. Expert Opin Drug Saf, 4:915–928.
118. Duncan R, Izzo L. 2005. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 57:2215– 2237.
119. Dhakar Ram C, Maurya Sheo Datta, Saluja Vikrant, From formulation variables to drug entrapment efficiency of microspheres: a technical review, Journal of Drug Delivery & Therapeutics; 2012, 2(6), 128-133.
120. Kukowska-Latallo JF, Candido KA, Cao ZY, Nigavekar SS, Majoros IJ, Thomas TP, Balogh LP, Khan MK, Baker JR. 2005. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 65:5317–5324.
121. Bhadra D, Bhadra S, Jain S, Jain NK. 2003. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm 257:111–124.
122. Chauhan AS, Jain NK, Diwan PV, Khopade AJ. 2004. Solubility enhancement of indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats. J Drug Target 12:575–583.
123. Sanghai B., Aggarwal G., & HariKumar S. Solid self microemulsifying drug deliviry system: a review. Journal of Drug Delivery And Therapeutics, 2013; 3(3), 168-174.
Statistics
812 Views | 713 Downloads
How to Cite
1.
Parajapati S, Maurya S, Das M, Tilak VK, Verma KK, Dhakar RC. POTENTIAL APPLICATION OF DENDRIMERS IN DRUG DELIVERY: A CONCISE REVIEW AND UPDATE. JDDT [Internet]. 14Mar.2016 [cited 5Aug.2021];6(2):71-8. Available from: https://jddtonline.info/index.php/jddt/article/view/1195

Most read articles by the same author(s)